The production of "loratrak hydrochloride", a new anti-tumor drug of Kangchen Pharmaceutical Co., Ltd., has been declared

Loratrek hydrochloride for injection, a national first-class anti-cancer drug developed by Kangchen Pharmaceutical Development Co., Ltd., is a non classical structure of folic acid thymidylate synthetase inhibitor, which belongs to cytotoxic anti-tumor drugs It can interfere with DNA synthesis of tumor cells, prevent cell division and proliferation, and play an anti-cancer role The drug has the advantages of good water solubility, not easy to accumulate in vivo, not easy to lead to renal toxicity, light side effects and rapid recovery, not easy to produce drug resistance Foreign studies have shown that it is effective for head and neck cancer, non-small cell lung cancer, liver cancer and other solid tumors Beijing Kangchen Pharmaceutical Co., Ltd.'s pharmaceutical production line news extension > > Kangchen pharmaceutical: the patent is the short hair, forthright character and agile style of the enterprise, which is the first impression of Wang Xijuan, chairman of Beijing Kangchen Pharmaceutical Co., Ltd (hereinafter referred to as Kangchen pharmaceutical) When she met Wang Xijuan, she had just attended a meeting, and she rushed from the urban area of Beijing to Kangchen pharmaceutical production and R & D headquarters in Miyun Economic and Technological Development Zone, 80 kilometers away Despite a moment's rest, Wang Xijuan began to recall to reporters the hardships and happiness of starting her own business Kangchen Pharmaceutical Co., Ltd broke the monopoly situation of foreign products in this field for a long time and created a new era of worry free hemostasis with its independently developed national class I new hemostasis product suling (Agkistrodon acutus hemagglutinase) Because of this, Wang Xijuan's understanding and perception of intellectual property is particularly profound In her opinion, intellectual property is the soul of an enterprise No matter how good the products and projects are, without independent intellectual property, it is difficult for an enterprise to develop continuously Wang Xijuan, who graduated from Peking University, was successfully assigned to work in a public institution after graduation In the eyes of outsiders, it's an enviable "iron rice bowl" job, but for Wang Xijuan, who likes challenges, it's not the life she wants After careful consideration, Wang Xijuan resolutely quit her original job and started her way of innovation and entrepreneurship In the early 1990s, with the spirit of hard work, Wang Xijuan soon earned the first barrel of gold in her life Li Zhixue, a multi-component hemagglutinase isolated from the venom of Agkistrodon halys, is very popular in China and often out of stock However, although the medicine is easy to sell, Wang Xijuan has no choice but to deal with the following problems "Foreign manufacturers limit the amount of drug put into the domestic market every year On the one hand, they have limited production capacity, and on the other hand, they want to control the retail price of drugs to keep at a high level through monopoly." Wang Xijuan told reporters One day, Wang Xijuan calmed down and thought carefully: there is a great clinical demand for hemostatic drugs in China, but this kind of drugs can only be imported, which is not only expensive, but also often in short supply China has a large number of Agkistrodon halys resources Can't we make better domestic snake venom hemagglutinase ourselves? With this bold idea, Wang Xijuan made another important choice in her life In 1996, she led her team to cooperate with the first-class research institutions in China and invested in the independent research and development of snake venom hemagglutinase At the beginning of 1998, in the venom of Agkistrodon acutus in South China, she and her team found a new active component with hemostatic effect, and started the drug development for 10 years People who have a little knowledge of the pharmaceutical industry know that the R & D of innovative drugs needs to invest a lot of money, and the risk is very high If the drug research and development is successful, it will bring huge profits to the enterprise If it fails, all the previous investment will be wasted Some insiders even think that the process of developing new drugs is more difficult than astronauts landing on the moon At the beginning of R & D, Wang Xijuan, who was "blind" and confident, had prepared for the manpower, material and financial resources needed for the research and development of new drugs, but the once abundant cash flow could not bear much "tossing", including personnel funds, test funds and raw material procurement costs Soon, there were some problems in Wang's capital chain At this time, if you choose to give up, it means that all the previous investment has gone through the water, and you continue to invest It is not known whether you can recover the cost in the future In desperation, Wang Xijuan and the shareholders of Kangchen pharmaceutical decided to sell their office building Haohai building at a low price, which temporarily solved the urgent need for funds Wang Xijuan's persistence and efforts have finally paid off After more than ten years of concentrated research and development, in 2009, the new hemostatic product "suling" of Kangchen pharmaceutical was officially put into production This product not only fills the blank of our country's independent intellectual property rights in snake venom hemagglutinase, but also is the only new hemostatic drug with single component and clear single target in the world "Unlike the multi-component of the imported hemostatic, lizhixue, Sulin has a single component purity of 99%, which greatly reduces the potential safety risks caused by impurities in biological preparations, as well as the cost of patients." Wang Xijuan told reporters that single component drugs have obvious advantages for drug quality control and safety The recognition of Su Ling in the market made Wang Xijuan feel a great sense of achievement At the same time, the national first-class anti-tumor drug "Dior" (loratroc hydrochloride) developed by Wang Xijuan led by the R & D team has also completed all clinical studies and is about to be put into production "As a pharmaceutical enterprise, innovation is endless Only by continuously launching new drugs can we maintain a leading position in the market." Wang Xijuan said 　　 It is understood that Kangchen pharmaceutical industry has established a complete R & D system from topic research, pre clinical research, intermediate test, registration and application, clinical research to intellectual property protection, forming a R & D pattern with "Sulin", "Dior" and "cx1003" as the core products, a number of innovative drugs as the key products, and continuous research and development of new dosage forms and new technologies Up to now, Kangchen pharmaceutical has submitted 28 patent applications for invention, including 17 international patent applications submitted through the Patent Cooperation Treaty (PCT) Among them, 11 domestic invention patent applications and 3 PCT international invention patent applications have been authorized At the same time, under the care and guidance of Miyun County Intellectual Property Office, the company has also established a relatively complete intellectual property protection system, and set up an intellectual property management department, which appoints special personnel to be responsible for intellectual property management, including patent information retrieval, patent application, patent file management, etc "Suling's success made me realize that intellectual property is the most important asset of an enterprise, and patent is an important tool to help an enterprise occupy a key position in the industrial chain." Wang Xijuan said that in the process of cooperation and negotiation with partners, any condition proposed by the other party will be agreed as long as it is allowed, even if it is to pay more money, and only intellectual property rights must be fully obtained by Kangchen pharmaceutical industry, which is not negotiable " Wang Xijuan said firmly Comments: Wang Xijuan's success, on the one hand, benefits from her boldness and persistence, on the other hand, comes from her preparation and grasp of the market Under the situation of monopoly of foreign products, Wang Xijuan has the courage to challenge the market More than ten years of persistence and waiting, only for the core products with independent intellectual property rights, and the success of products and market recognition is the best return for her Paying attention to patents and making good use of them, "suling" is not only hemostasis for patients, but also "hematopoiesis" for Kangchen pharmaceutical industry